Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05057637 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Impact of Optical Coherence Tomography on the Endovascular Treatment Planning of Femoropopliteal Disease

Study acronym: Optimo
StatusActive, Not Recruiting
PhaseNot specified
Started2022-03-09
View on ClinicalTrials.gov ↗

Amendment history

2026-01-05
minor
Study Status v6
Primary completion dateestimated 2025-09→confirmed 2025-12-12
Completion date2025-10→2027-04
2025-08-04
notable
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v5
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-05→2025-09
Completion date2025-05→2025-10
Study sitesdetails revised at 1 of 1 site
2025-04-07
minor
Study Status, Oversight v4
Primary completion date2024-12→2025-05
Completion date2024-12→2025-05
2024-11-20
minor
Study Status, Oversight v3
Primary completion date2024-06→2024-12
2023-07-31
minor
Study Status, Study Description, Eligibility v2
Primary completion date2022-12→2024-06
Start date2021-10-18→2022-03-09
Eligibility criteria-38 characters
[...] treatment of femoropopliteal stenotic lesions with a Supera interwoven nitinol stent or Absolute nitinol stent Clinically and hemodynamically stable Exclusion Criteria: Occluded superficial femoral artery or popliteal artery Origin stenosis of the superficial femoral artery (within 5 cm of the bifurcation) Superficial femoral artery and/or popliteal artery diameter [...]
2022-05-02
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-09→confirmed 2021-10-18
Study sites0→1
2021-09-15
minor
Original filing
Rationale: Peripheral arterial disease is a severe clinical problem with an increasing prevalence, due to an ageing population. Endovascular treatment, usually using stents, is recommended for most lesions in the femoropopliteal tract. The patency of these stents is influenced by several factors, including stent sizing and stent positioning. Current procedural planning of femoropopliteal disease is primarily based on single-plane digital subtraction angiographies (DSA). This modality provides a 2-dimensional image of the vessel lumen, which may be suboptimal for stent sizing. It can therefore be difficult to choose the optimal stent position as minor lesions may be missed. Suboptimal treatment could result in unfavourable levels of wall shear stress causing the vessel wall to be more susceptible to neo-intimal hyperplasia ultimately causing restenosis and stent failure. Intravascular optical coherence tomography (OCT) is able to visualize the arterial wall with a micrometer resolution, which could result in better stent sizing. Furthermore, OCT is able to visualize different layers in the vessel wall and identify unhealthy areas, which may lead to a more optimal stent placement as unhealthy areas can be covered completely. Moreover, OCT provides detailed patient-specific geometries necessary to develop reliable computational fluid dynamics (CFD) models that simulate blood flow in stented arteries and calculate wall shear stresses, which could predict stent patency. Objective: To investigate in a clinical study how often the use of intravascular optical coherence tomography for femoropopliteal stenotic lesions leads to alterations in treatment planning before and after stent placement, in comparison to traditional digital subtraction angiography-based treatment planning. Study design: Exploratory observational study. Study population: 25 patients with femoropopliteal stenotic lesions who are treated with a Supera interwoven nitinol stent or Absolute nitinol stent. Main study parameters/endpoints: The percentage of procedures in which OCT changed the DSA-based treatment planning before and after stent placement to investigate the impact of OCT imaging on treatment planning.
Trial Details
NCT Number NCT05057637
Lead Sponsor Rijnstate Hospital
Collaborators: University of Twente, Abbott
Conditions Femoropopliteal Stenosis
Enrollment 25 participants
Start Date 2022-03-09
Primary Completion 2025-12-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-07